Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glaucoma. - Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glau
- Conditions
- Rubeotic glaucoma secondary to ischaemic proliferative retinopathies
- Registration Number
- EUCTR2007-000585-21-IE
- Lead Sponsor
- Royal Victoria Eye and Ear hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients with rubeotic glaucoma ( iris or angle neovascularisation and intraocular pressure > 21 mmHg)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Only eye
Women of childbearing potential
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To assess the effectiveness of intravitreal bevacizumab in treating rubeotic glaucoma when compared with conventional treatment. <br><br>Primary outcomes: <br>1. Iris neovascularisation <br>2. IOP <br>3. IOP medications <br>4. Pain <br>5. Visual acuity <br>6. Need for enucleation<br><br>;Secondary Objective: Secondary outcomes: Quality of life, OCT.;Primary end point(s): Primary end points: <br>1. Iris neovascularisation <br>2. IOP <br>3. IOP medications <br>4. Pain <br>5. Visual acuity <br>6. Need for enucleation
- Secondary Outcome Measures
Name Time Method